Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device compan...
Cardiovascular Systems, Inc., based in St. Paul...
BioSpecifics Technologies Corp. is a biopharmaceutical company that is the origina...
BioSpecifics Technologies Corp. is a biopharmac...
CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues ...
CollPlant is a regenerative medicine company fo...
We are a clinical-stage biopharmaceutical company focused on improving the lives o...
We are a clinical-stage biopharmaceutical compa...
Headquartered in Waltham, Massachusetts, we develop and deliver innovative medicin...
Headquartered in Waltham, Massachusetts, we dev...
We are an innovative biopharmaceutical company developing therapies to treat the m...
We are an innovative biopharmaceutical company ...
Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in ...
Genprex Inc is a U.S.-based clinical-stage gene...
Join the National Investor Network and get the latest information with your interests in mind.